Metastatic Prostatic Adenocarcinoma Clinical Trial
Official title:
A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma.
The purpose of this study is to look at patient outcomes when docetaxel is started prior to ADT with degarelix.
This study will look at two drugs, docetaxel and degarelix, which are both FDA approved for the treatment of prostate cancer. Docetaxel is a standard chemotherapy treatment for metastatic prostate cancer. Degarelix is an androgen deprivation therapy (ADT) agent that decreases the amount of testosterone in the body, which helps to fight tumor growth. Usually, docetaxel is given after ADT. This study will look at how your cancer changes when docetaxel is started before ADT. You are being asked to participate in this study because you have metastatic prostate cancer that can be treated with docetaxel and ADT. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03678025 -
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
|
Phase 3 | |
| Completed |
NCT02458716 -
Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
|
Phase 1 | |
| Completed |
NCT04090775 -
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma
|
Phase 2 | |
| Terminated |
NCT04085991 -
Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer
|
Phase 2 | |
| Terminated |
NCT01253642 -
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
|
Phase 2 | |
| Terminated |
NCT03827473 -
Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
|
Phase 2 |